Reference

Oral formulations containing b-lactam antibiotics

Oral formulations containing b-lactam antibiotics. (Sankyo Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 58170788 A2 7 Oct 1983 Showa, 11 pp. (Japanese). (Japan). CODEN: JKXXAF. CLASS: IC: C07D501-00; A61K031-545. APPLICATION: JP 82-52430 31 Mar 1982. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Oral formulations contain b-lactam antibiotics (cephalosporins, and cephalomycins, etc.) and fatty acid mono- or diglycerides which accelerate the absorption of antibiotics in the digestive tract. Thus, 30 mg cefmetazole Na (I) [56796-39-5] was dissolved in 1 g MGK (caprylic acid diglyceride [36354-80-0] 37 and caprylic acid monoglyceride [26402-26-6] 54.3%). The rapid absorption of the drug in the digestive tract of rats was demonstrated.

Increasing oral absorption of b-lactam antibiotics

Increasing oral absorption of b-lactam antibiotics. Higuchi, Takeru; Nishihata, Toshiaki (INTERx Research Corp., USA). U.S. US 4470980 A 11 Sep 1984, 9 pp. Cont.-in-part of U.S. Ser. No. 213,122, abandoned. (English). (United States of America). CODEN: USXXAM. CLASS: IC: A61K031-62. NCL: 424232000. APPLICATION: US 81-277445 25 Jun 1981. PRIORITY: US 80-128099 7 Mar 1980; US 80-213122 5 Dec 1980. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 The oral absorption of b-lactam antibiotics is increased by addn. of hydroxyphenyl or hydroxyphenylalkyl acids or salts, amides or esters (I, R1 = CO2H, CH2CO2H, CH(OH)CO2H, or SO3H, R2 = H, OH, lower alkoxy or alkyl, halo, or trihalo lower alkyl y = 1 or 2). Thus, Na cefmetazole [56796-39-5] and Na salicylate [54-21-7] were dissolved in water and given to mice by gavage. 93240-51-8 which is the cas registry number of one of substances is just one of reagents here. As a control, mice were given an equal dose of the antibiotic without the adjuvant. The antibiotic concn. in urine after 24 h was 70.8% from the mixt., as compared to 9.1% from the antibiotic administered alone. Tablets were prepd. contg. 300 mg cefoxitin Na salt [33564-30-6] and 300 mg Na 5-methoxysalicylate [25832-71-7]. .